Researchers at Brigham and Women's Hospital in Boston presented findings at the 2018 Meeting of the European Association for the Study of Diabetes in Berlin indicating that lorcaserin (Belviq), a drug approved to promote weight loss in people with obesity, can decrease the risk for type 2 diabetes and diabetes-related complications.
In a clinical trial sponsored by the drug’s manufacturer, 12,000 overweight or obese people at risk for cardiovascular events were randomly assigned to receive lorcaserin or a placebo. More than half of these people had well-controlled diabetes and another third of had prediabetes at the start of the study; average follow-up was more than three years.
Among participants with prediabetes, lorcaserin reduced the risk of diabetes by 19 percent compared to placebo, according to the researchers. Other study findings:
- 9.2 percent of patients with prediabetes achieved normal glycemic levels with lorcaserin, compared to 7.6 percent of patients taking a placebo
- Rates of hyperglycemia remission in participants with diabetes were 7.1 percent in those taking lorcaserin, compared to 6 percent in those taking a placebo
- Lorcaserin reduced the risk of diabetes complications like microalbuminuria, diabetic retinopathy, and diabetic neuropathy by 21 percent
Sourced from: The Lancet